S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

FATE Fate Therapeutics Inc

3.89

0.19 (5.14%)

Last Updated: 09:58:16

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Fate Therapeutics Charts.

Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Fate Therapeutics Charts.

Fate Therapeutics Inc News

Form 8-K - Current report
Thursday 9 May 2024 (2 hours ago) • Edgar (US Regulatory)

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Thursday 9 May 2024 (3 hours ago) • GlobeNewswire Inc.

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
Monday 6 May 2024 (3 days ago) • GlobeNewswire Inc.

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Friday 3 May 2024 (6 days ago) • GlobeNewswire Inc.

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Monday 22 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Wednesday 3 April 2024 (1 month ago) • GlobeNewswire Inc.

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Tuesday 19 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 5 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Monday 4 March 2024 (2 months ago) • Edgar (US Regulatory)

Fate Therapeutics to Present at Upcoming March Investor Conferences
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.

More Fate Therapeutics Inc News Articles

Ronn Motor (PK)

Brookmount Explorations (PK)

Globestar Therapeutics (PK)

MicroCloud Hologram

Ecare Solutions (PK)

1812 Brewing (PK)

Kraig Biocraft Laborator... (QB)

Kona Gold Beverage (PK)

Innovation Pharmaceuticals (CE)

Bioelectronics (PK)

Elite Pharmaceuticals (QB)

Intergrated Cannabis Sol... (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions